BioSpace News Archive

On October 6, 2021, Bristol Myers Squib and Celgene terminated the original deal related to Abraxane and gave BeiGene 180 days of notice that it was withdrawing Abraxane from the deal.

Transition Bio named Gregory Miller as chief executive officer, Prof. Tuomas Knowles as chief technology officer and Martin Kulander as chief operating officer, among several others.

According to CNN, Califf is being vetted by the administration of Joe Biden, who served as vice president to Obama.

Biopharma and life sciences companies strengthen their leadership teams and executive boards with these Movers & Shakers.

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that, following Australian Foreign Investment Review Board (“FIRB”) approval, it officially closed the purchase of 360biolabs®.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH) portfolio will be presented at CHEST 2021, the annual meeting of the American College of Chest Physicians, held virtually October 17-20.

CytoSorbents Corporation announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb-ATR™ Antithrombotic Removal System for intraoperative removal of ticagrelor during cardiothoracic surgery.

Vedanta Biosciences today announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary.

OnKure, Inc. today announced the appointment of Jennifer R. Diamond, M.D., as Chief Medical Officer.

CytoDyn Inc. today announced that the Delaware Court of Chancery found that CytoDyn’s Board of Directors properly rejected a nomination notice presented by an activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Activist Group”).